Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Diabetes Mellitus
Interventions
Generex Oral-lyn™, Regular human insulin
Drug
Lead sponsor
Generex Biotechnology Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
2001 Santa Monica Blvd Suite 390W, California • 1150 N. 35th Ave Suite 590, Florida • 7400 North Shadeland Ave, Indiana + 5 more
Conditions
Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
Interventions
Insulin glargine, insulin NPH
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Maywood, Illinois
Recruiting Phase 2 Interventional

DETERMINE: Detemir vs NPH

NCT05124457
Conditions
Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin Detemir, Insulin NPH
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
9 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Diabetes Mellitus
Interventions
30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetic Ketoacidosis
Interventions
insulin glargine+ glulisine, NPH + Regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Minneapolis, Minnesota
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine insulin, NPH insulin and regular insulin, lispro insulin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Phase 4 Interventional Results available

Insulin Glargine Versus Twice-Daily NPH

NCT00687453
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine at bedtime instead of NPH, NPH twice-daily
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Type 2 Diabetes
Interventions
Detemir + aspart insulin before meals, NPH insulin + regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison Study of Insulin Glargine and NPH Insulin

NCT01854723
Conditions
Diabetes
Interventions
Switching to NPH insulin, Continuation of insulin glargine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
Up to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Diabetes Mellitus
Interventions
Insulin, Isophane, insulin glargine
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

NCT00645827
Conditions
Glucose, Blood
Interventions
IICE Dosing, Healthcare Provider dosing
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Insulin protocol
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers Results available

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

NCT01837680
Conditions
Diabetes, Gestational, Diabetes, Type 2
Interventions
Insulin
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes, Gestational Diabetes
Interventions
human insulin, insulin NPH, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Gestational Diabetes, Pregnancy Related
Interventions
Insulin
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Rochester, New York • Philadelphia, Pennsylvania
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH/Regular 70/30 mix, insulin aspart protamine/insulin aspart 70/30 mix
Drug
Lead sponsor
Dennis G. Karounos, M.D.
Federal
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH and regular insulin, glargine and humalog
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Moreno Valley, California
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Conditions
Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions
Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio